Project Directores: Dr. Luis Paz-Ares, Dr. Luis Álvarez-Vallina. Centres: Hospital Universitario 12 de Octubre de Madrid, Centro Nacional de Investigaciones Oncológicas (CNIO). Introduction During the last few years, the conception of how cancer develops has changed radically. Tumours are no longer considered isolated entities that grow in isolation from their environment, and it has been
Principal Researcher: Dr. Miguel Ángel Quintela Center: CNIO, Madrid Introduction: Breast cancer is the most common cancer in the UK. Around 55,200 people are diagnosed with breast cancer every year in the UK. That is around 150 people a day. 15 out of 100 (15%) of all newly diagnosed cancers in the UK are breast cancer. It is
Principal Investigator: Dra. Mª Elena Élez Centre: Vall d’Hebrón Institute of Oncology (Barcelona) Introduction: There are around 42,300 new bowel cancer cases in the UK every year, that’s more than 110 every day. Bowel cancer is the 4th most common cancer in the UK, accounting for 11% of all new cancer cases. It is also the 2nd
Introduction: The CRIS Unit comprises three facilities, which have been set up to undertake the three most important phases in the development of new therapies, primarily: Translational Oncology Laboratory: studies are carried out in this laboratory to identify new targets and therapeutic strategies. New Compound Screening Laboratory: once new therapeutic strategies have been designed, the process of testing a large number of drugs or compounds is started. Using high-performance techniques, those with the greatest
Principal Investigator: Dr. Enrique Grande Centre: Fundación MD Andersen Center, Madrid Introduction: Bladder cancer is a relatively common tumour, with an estimated 10,233 new cases a year in the UK. It is more common with ageing, with 70% of cases occurring in patients over the age of 65 years. It is a type of cancer that is often
principal investigator: Dr. Mariano Barbacid Center: Centro Nacional de Investigaciones Oncológicas (CNIO) Context: Pancreatic ductal adenocarcinoma accounts for 90% of malignant pancreatic tumours. It poses a massive medical challenge for a variety of reasons. Firstly, it is one of the most aggressive and fastest spreading tumours from which a staggering 95% of patients do not survive. Secondly, it is generally diagnosed late and, as there are also no effective treatments for it, mortality rates are extremely high. Pancreatic cancer is the 10th most common cancer
One of the most promising avenues of research in the quest for new ovarian cancer treatments is the manipulation of the immune system, namely Immunotherapy. The project’s current focus is on various aspects of this type of therapy. Several projects are currently being developed that focus on the immune system as a gateway to better therapies.
Principal Investigators: Dr Alberto Ocaña, Dr Atanasio Pandiella Centres: CHUA (University Hospital Complex of Albacete) – Albacete and CIC (Cancer Research Centre) – Salamanca Breast cancer is the most common cancer in the UK. Around 55,200 people are diagnosed with breast cancer every year in the UK. That is around 150 people a day. 15 out of 100 (15%)
Principal Researcher: Dr David Olmos and Dr Elena Castro. Centres: Spanish National Cancer Research Centre (CNIO), IBIMA (Biomedical Research Institute of Malaga). Background: In the UK, about 1 in 8 men will be diagnosed with prostate cancer in their lifetime. Prostate cancer is the most common cancer in men. More than 47,500 men are diagnosed with
Researcher leading the project: Dr. Joaquín Martínez Centres developing the research: 12 de Octubre University Hospital, Madrid, Spanish National Cancer Research Centre (CNIO). Context Haematological, or blood cell tumours represent largely incurable cancers today. Blood cancer is the fifth most common cancer in the UK, with over 40,000 people being diagnosed with it every year. There are about